Home » News » Drug Sponsors » Shire shows strong profits for Q1

Shire shows strong profits for Q1

Tuesday, May 3, 2011

Shire Pharmaceuticals has strong results for the first quarter, with its attention-deficit hyperactivity disorder (ADHD) drugs driving growth, according to Pharma Times.

Net income came in at $211.3 million, up 27%, while revenues increased 19% to $972 million. Turnover was driven by the ADHD drug Vyvanse (lisdexamfetamine dimesylate), which grew 31% to $202.3 million, and Adderall XR (mixed amphetamine salts) brought in $111.2 million, up 21%. Another ADHD drug, Intuniv (guanfacine), had sales of $41.9 million.

Shire rare diseases portfolio also fared particularly well, with Replagal (agalsidase alfa) for Fabry disease increased 55% to $105.4 million. Vpriv (velaglucerase alfa) for Gaucher’s disease, brought in $59 million, up 917. The Hunter Syndrome therapy Elaprase (idursulfase) rose 3% to $103.5 million.

As for Shire’s other products, Pentasa (mesalamine) climbed 11% to $64.5 million, and the firm’s newer ulcerative colitis drug Lialda/Mezavant brought in $87.1 million, up 37%.

The company also revealed positive phase II data looking at Vyvanse as a potential adjunctive treatment in for the negative symptoms of schizophrenia. Plans for a study in binge eating disorder as well as the continuing phase III program looking at Vyvanse for major depressive disorder may be underway as well.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!